Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions

P. Dundr, K. Simon, K. Němejcová, M. Bártů, I. Tichá, R. Michálková, R. Jakša, Z. Věcková, O. Kodet,

. 2019 ; 29 (2) : 157-162. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028083

Grantová podpora
NV16-30954A MZ0 CEP - Centrální evidence projektů

In several solid tumors, an increased stathmin expression is associated with both poor prognosis and resistance to certain chemotherapy types. However, the data regarding melanocytic lesions are very limited. The goals of our study are as follows: the assessment of stathmin expression in benign and malignant melanocytic lesions, and the significance of its expression for the differential diagnostics between benign and malignant lesions; the analysis of the prognostic significance of stathmin expression in melanoma; and the evaluation of stathmin expression in melanoma and melanoma metastases with respect to possible therapeutic targeting. Immunohistochemical analysis of stathmin expression was done in 323 melanocytic lesions, including 205 primary cutaneous melanomas, 60 melanoma metastases, and 58 melanocytic nevi. Stathmin expression was found in all analyzed groups of melanocytic lesions. Using the H-scoring system, the observed intensity of expression was as follows: melanocytic nevi: 146.1 (mean) and 150 (median); melanomas: 116.7 (mean) and 110 (median); and melanoma metastases: 136.8 (mean) and 140 (median). The stathmin expression was significantly lower in the cohort of primary melanomas when compared with metastases and nevi (P=0.001). The stathmin expression showed no prognostic significance. The high stathmin expression in melanoma suggests that stathmin might be a promising marker for therapeutic targeting in ongoing clinical trials. Compared with several other solid tumors, stathmin expression in melanoma showed no prognostic significance. The potential use of stathmin expression in differential diagnostics is limited by its common expression, and despite the statistically significant differences between nevi and melanoma, it may not be used in this setting.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028083
003      
CZ-PrNML
005      
20190823095850.0
007      
ta
008      
190813s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/CMR.0000000000000550 $2 doi
035    __
$a (PubMed)30422880
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dundr, Pavel $u Institute of Pathology.
245    10
$a Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions / $c P. Dundr, K. Simon, K. Němejcová, M. Bártů, I. Tichá, R. Michálková, R. Jakša, Z. Věcková, O. Kodet,
520    9_
$a In several solid tumors, an increased stathmin expression is associated with both poor prognosis and resistance to certain chemotherapy types. However, the data regarding melanocytic lesions are very limited. The goals of our study are as follows: the assessment of stathmin expression in benign and malignant melanocytic lesions, and the significance of its expression for the differential diagnostics between benign and malignant lesions; the analysis of the prognostic significance of stathmin expression in melanoma; and the evaluation of stathmin expression in melanoma and melanoma metastases with respect to possible therapeutic targeting. Immunohistochemical analysis of stathmin expression was done in 323 melanocytic lesions, including 205 primary cutaneous melanomas, 60 melanoma metastases, and 58 melanocytic nevi. Stathmin expression was found in all analyzed groups of melanocytic lesions. Using the H-scoring system, the observed intensity of expression was as follows: melanocytic nevi: 146.1 (mean) and 150 (median); melanomas: 116.7 (mean) and 110 (median); and melanoma metastases: 136.8 (mean) and 140 (median). The stathmin expression was significantly lower in the cohort of primary melanomas when compared with metastases and nevi (P=0.001). The stathmin expression showed no prognostic significance. The high stathmin expression in melanoma suggests that stathmin might be a promising marker for therapeutic targeting in ongoing clinical trials. Compared with several other solid tumors, stathmin expression in melanoma showed no prognostic significance. The potential use of stathmin expression in differential diagnostics is limited by its common expression, and despite the statistically significant differences between nevi and melanoma, it may not be used in this setting.
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanocyty $x metabolismus $x patologie $7 D008544
650    _2
$a melanom $x krev $x patologie $7 D008545
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a nádory kůže $x krev $x patologie $7 D012878
650    _2
$a stathmin $x metabolismus $7 D050777
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Simon, Karol $u Institute of Pathology.
700    1_
$a Němejcová, Kristýna $u Institute of Pathology.
700    1_
$a Bártů, Michaela $u Institute of Pathology.
700    1_
$a Tichá, Ivana $u Institute of Pathology.
700    1_
$a Michálková, Romana $u Institute of Pathology.
700    1_
$a Jakša, Radek $u Institute of Pathology.
700    1_
$a Věcková, Zuzana $u Institute of Pathology.
700    1_
$a Kodet, Ondřej $u Department of Dermatology and Venereology, First Faculty of Medicine, Charles University and General University Hospital in Prague. Institute of Anatomy, First Faculty of Medicine, Charles University, Prague, Czech Republic.
773    0_
$w MED00003323 $t Melanoma research $x 1473-5636 $g Roč. 29, č. 2 (2019), s. 157-162
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30422880 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190823100105 $b ABA008
999    __
$a ok $b bmc $g 1433232 $s 1066543
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 29 $c 2 $d 157-162 $e - $i 1473-5636 $m Melanoma research $n Melanoma Res $x MED00003323
GRA    __
$a NV16-30954A $p MZ0
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...